Cargando…

The clinical outcome of recurrent sacral chordoma with further surgical treatment

Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yongkun, Li, Yuan, Liu, Weifeng, Xu, Hairong, Niu, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314672/
https://www.ncbi.nlm.nih.gov/pubmed/30593146
http://dx.doi.org/10.1097/MD.0000000000013730
_version_ 1783384140275515392
author Yang, Yongkun
Li, Yuan
Liu, Weifeng
Xu, Hairong
Niu, Xiaohui
author_facet Yang, Yongkun
Li, Yuan
Liu, Weifeng
Xu, Hairong
Niu, Xiaohui
author_sort Yang, Yongkun
collection PubMed
description Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operations and disturbed local anatomical structures may increase the risk of reoperation. Most previous studies have focused on the primary tumor; there are very few reports on the clinical diagnosis, treatment, and prognosis of recurrent sacral chordomas. Thirty-four patients with recurrent sacral chordomas from 1979 to 2014 were included in this study. The patients comprised 25 men and 9 women with an average age of 50.7 (24–75) years. The average time until recurrence was 19.4 (4–51) months postoperatively, and 85.3% of the recurrent tumors were located in bone. The patients had an average of 1.2 (1–3) recurrences before further operations were performed in our hospital. The mean maximum tumor diameter was 8.1 (4.6–12.0) cm. Thirty-one patients underwent further tumor resection in our hospital. The postoperative recurrence, metastasis, and survival results were followed and analyzed. The mean follow-up after surgical treatment of recurrence was 49.6 (12–144) months. Nine patients (37.5%) developed recurrence again after an average of 26.7 months. The 3-year and 5-year recurrence-free survival rate was 69.4% and 63.1%, respectively. Multivariate analysis showed that the tumor level within the sacrum (P = .001) and the surgical margin (P = .001) were significant recurrence-related factors. Four patients (16.7%) developed lung metastasis. Eighteen patients were alive at last follow-up. The 5-year and 10-year survival rate after surgical treatment of recurrence was 67.3% and 53.9%, respectively. Most recurrent tumors are located in bone, and a safe osteotomy margin is important. The surgical margin is the only controllable factor of further tumor recurrence. Some patients with recurrence achieve long survival and obtain a clinical benefit from repeated operations if complete resection is achieved.
format Online
Article
Text
id pubmed-6314672
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63146722019-01-14 The clinical outcome of recurrent sacral chordoma with further surgical treatment Yang, Yongkun Li, Yuan Liu, Weifeng Xu, Hairong Niu, Xiaohui Medicine (Baltimore) Research Article Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operations and disturbed local anatomical structures may increase the risk of reoperation. Most previous studies have focused on the primary tumor; there are very few reports on the clinical diagnosis, treatment, and prognosis of recurrent sacral chordomas. Thirty-four patients with recurrent sacral chordomas from 1979 to 2014 were included in this study. The patients comprised 25 men and 9 women with an average age of 50.7 (24–75) years. The average time until recurrence was 19.4 (4–51) months postoperatively, and 85.3% of the recurrent tumors were located in bone. The patients had an average of 1.2 (1–3) recurrences before further operations were performed in our hospital. The mean maximum tumor diameter was 8.1 (4.6–12.0) cm. Thirty-one patients underwent further tumor resection in our hospital. The postoperative recurrence, metastasis, and survival results were followed and analyzed. The mean follow-up after surgical treatment of recurrence was 49.6 (12–144) months. Nine patients (37.5%) developed recurrence again after an average of 26.7 months. The 3-year and 5-year recurrence-free survival rate was 69.4% and 63.1%, respectively. Multivariate analysis showed that the tumor level within the sacrum (P = .001) and the surgical margin (P = .001) were significant recurrence-related factors. Four patients (16.7%) developed lung metastasis. Eighteen patients were alive at last follow-up. The 5-year and 10-year survival rate after surgical treatment of recurrence was 67.3% and 53.9%, respectively. Most recurrent tumors are located in bone, and a safe osteotomy margin is important. The surgical margin is the only controllable factor of further tumor recurrence. Some patients with recurrence achieve long survival and obtain a clinical benefit from repeated operations if complete resection is achieved. Wolters Kluwer Health 2018-12-28 /pmc/articles/PMC6314672/ /pubmed/30593146 http://dx.doi.org/10.1097/MD.0000000000013730 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Yang, Yongkun
Li, Yuan
Liu, Weifeng
Xu, Hairong
Niu, Xiaohui
The clinical outcome of recurrent sacral chordoma with further surgical treatment
title The clinical outcome of recurrent sacral chordoma with further surgical treatment
title_full The clinical outcome of recurrent sacral chordoma with further surgical treatment
title_fullStr The clinical outcome of recurrent sacral chordoma with further surgical treatment
title_full_unstemmed The clinical outcome of recurrent sacral chordoma with further surgical treatment
title_short The clinical outcome of recurrent sacral chordoma with further surgical treatment
title_sort clinical outcome of recurrent sacral chordoma with further surgical treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314672/
https://www.ncbi.nlm.nih.gov/pubmed/30593146
http://dx.doi.org/10.1097/MD.0000000000013730
work_keys_str_mv AT yangyongkun theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT liyuan theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT liuweifeng theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT xuhairong theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT niuxiaohui theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT yangyongkun clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT liyuan clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT liuweifeng clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT xuhairong clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment
AT niuxiaohui clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment